Stem cell toxicity of oxazaphosphorine metabolites in comparison to their antileukemic activity

Biochemical Pharmacology

Volumn 63, Issue 7, 2002, Pages 1337-1341

  Brueggemann, Svenja K ^a   Schlenke, Peter ^a   Klich, Stephanie ^a   Deeken, Michael ^a   Peters, Stefan O ^a   Wagner, Thomas ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

Author keywords

4 Hydroxy cyclophosphamide; 4 Hydroxy ifosfamide; Alkylating agents; Antileukemic activity; Chloroacetaldehyde; Stem cell toxicity

Indexed keywords

CHLOROACETALDEHYDE; CYCLOPHOSPHAMIDE; DRUG METABOLITE; IFOSFAMIDE; MAFOSFAMIDE; OXAZAPHOSPHORINE DERIVATIVE;

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASSAY; CELL PROTECTION; CLINICAL ARTICLE; CLONOGENESIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG SPECIFICITY; HUMAN; HUMAN CELL; LEUKEMIA CELL; PRIORITY JOURNAL; SOLID TUMOR; STEM CELL;

ACETALDEHYDE; ALKYLATING AGENTS; ANTINEOPLASTIC AGENTS; CYCLOPHOSPHAMIDE; DRUG SCREENING ASSAYS, ANTITUMOR; HEMATOPOIETIC STEM CELLS; HUMANS; IFOSFAMIDE; TUMOR CELLS, CULTURED; TUMOR STEM CELL ASSAY;

EID: 0036536439     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(02)00868-7     Document Type: Article

References (41)

1. Some studies of the active intermediates formed in the microsomal metabolism of cyclophosphamide and isophosphamide
2. Metabolism of cyclophosphamide
3. Hallucinations and ifosfamide-induced neurotoxicity
4. Dechloroethylation of ifosfamide and neurotoxicity
5. Ifosfamide pharmacokinetics and neurotoxicity
6. Ifosfamide, mesna, and nephrotoxicity in children
7. Modulation of P450-dependent ifosfamide pharmacokinetics: A better understanding of drug activation in vivo
8. Ifosfamide cytotoxicity on human tumor and renal cells: Role of chloroacetaldehyde in comparison to 4-hydroxyifosfamide
9. Metabolism of ifosfamide to chloroacetaldehyde contributes to antitumor activity in vivo
10. Ifosfamide-pharmacology, safety and therapeutic potential
11. Cyclophosphamide vs. ifosfamide: Final report of a randomized phase II trial in adult soft tissue sarcomas
12. Differential sensitivity of adherent CFU-blast, CFU-mix, BFU-E, and CFU-GM to mafosfamide: Implications for adjusted dose purging in autologous bone marrow transplantation
13. Characterization of late and early hematopoietic progenitor/stem cell sensitivity to mafosfamide
14. Pharmacological purging of minimal residual disease from peripheral blood stem cell collections of acute myeloblastic leukemia patients: Preclinical studies
15. Establishment of a reliable experimental procedure for bone marrow purging with mafosfamide (ASTA Z 7557)
16. Sensitivity of human CFU-GM to mafosfamide: Analysis of the factors affecting individual variations
17. Mafosfamide-purged peripheral blood stem cell harvest: Case report of a 54-year-old patient with relapsed acute myeloid leukemia
18. Purging of G-CSF-mobilized peripheral autografts in acute leukemia with mafosfamide and amifostine to protect normal progenitor cells
19. Direct demonstration of elevated aldehyde dehydrogenase in human hematopoietic progenitor cells
20. Aldehyde dehydrogenase activity as the basis for the relative insensitivity of murine pluripotent hematopoietic stem cells to oxazaphosphorines
21. Role for aldehyde dehydrogenase in survival of progenitors for murine blast cell colonies after treatment with 4-hydroperoxycyclophosphamide in vitro
22. Restoration of sensitivity to oxazaphosphorines by inhibitors of aldehyde dehydrogenase activity in cultured oxazaphosphorine-resistant L1210 and cross-linking agent-resistant P388 cell lines
23. Identification and characterization of a novel class 3 aldehyde dehydrogenase overexpressed in a human breast adenocarcinoma cell line exhibiting oxazaphosphorine-specific acquired resistance
24. Phenolic antioxidant-induced overexpression of class 3 aldehyde dehydrogenase and oxazaphosphorine-specific resistance
25. The effect of ifosfamide and its metabolites on intracellular glutathione levels in vitro and in vivo
26. Molecular mechanisms of chloroacetaldehyde-induced cytotoxicity in isolated rat hepatocytes
27. Influence of buthionine sulfoximine on the lethality of ifosfamide and ifosfamide-induced urotoxicity in mice
28. Ifosfamide induced depletion of glutathione in human peripheral blood lymphocytes and protection by mesna
29. Formation of interstrand cross-links in chloroacetaldehyde-treated DNA demonstrated by ethidium bromide fluorescence
30. 2-Chloroacetaldehyde and 2-chloroacetal are potent inhibitors of DNA synthesis in animal cells
31. Identification of glutathione S-transferase as a determinant of 4-hydroperoxycyclophosphamide resistance in human breast cancer cells
32. Chloroacetaldehyde-induced hepatocyte cytotoxicity. Mechanisms for cytoprotection
33. Suppression of plasma glutathione peroxidase activity by ifosfamide
34. Ifosfamide: Should the honeymoon be over?
35. Assessment of aldehyde dehydrogenase in viable cells
36. Effect of aldehyde dehydrogenase inhibitors on the ex vivo sensitivity of human multipotent and committed hematopoietic progenitor cells and malignant blood cells to oxazaphosphorines
37. Role of aldehyde dehydrogenase in cyclophosphamide-resistant L1210 leukemia
38. Characterization of cytosolic aldehyde dehydrogenase from cyclophosphamide resistant L1210 cells
39. Determination of the urinary excretion of ifosfamide and its phosphorated metabolites by phosphorus-31 nuclear magnetic resonance spectroscopy
40. A new approach to the study of ifosfamide metabolism by the analysis of human body fluids with 31P nuclear magnetic resonance spectroscopy
41. The effect of route of administration and fractionation of dose on the metabolism of ifosfamide